Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Experts develop recommendations to determine why nearly two-thirds of Americans with AD are women

A group of experts has developed consensus recommendations for future research directions to determine why nearly two-thirds of Americans with Alzheimer's disease (AD) are women.

7 Sep 2012

Hopes dashed for ginkgo biloba in Alzheimer’s disease

The GuidAge trial of ginkgo biloba extract in people with evidence of memory problems confirms that the treatment does not reduce their risk for progression to Alzheimer’s disease.

6 Sep 2012

Alzheimer’s disease is not prevented by ginkgo biloba

Ginkgo biloba extract does not significantly reduce the likelihood of diagnosis of Alzheimer’s disease in older people, according to the results of the largest ever Alzheimer’s prevention study in Europe, published in The Lancet Neurology.

6 Sep 2012

Eliminating jnk3 enzyme leads to 90% reduction in Alzheimer's plaque-forming compounds

Scientists have found that eliminating an enzyme from mice with symptoms of Alzheimer's disease leads to a 90 percent reduction in the compounds responsible for formation of the plaques linked to Alzheimer's disease.

6 Sep 2012

Sleep disruptions may be among the first signs of Alzheimer's

Sleep disruptions may be among the earliest indicators of Alzheimer's disease, scientists at Washington University School of Medicine in St. Louis report Sept. 5 in Science Translational Medicine.

6 Sep 2012

Out-of-pocket spending on health care in old age puts significant strain on finances

The protection of the savings of the elderly-one of the primary goals of Medicare-is under threat from a combination of spiraling healthcare costs and increased longevity. As the government attempts to reduce Medicare costs, one suggestion is that the elderly could pay a larger proportion of the costs of their healthcare. But exactly how much would this be and what impact would it have on their finances?

6 Sep 2012

Newly discovered neuronal pathway plays key role in controlling bone density during adolescence

Researchers at the Hebrew University of Jerusalem have discovered that a neuronal pathway -- part of the autonomic nervous system -- reaches the bones and participates in the control of bone development.

5 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.

4 Sep 2012

People with normal blood sugar range may be at increased risk of brain shrinkage

People whose blood sugar is on the high end of the normal range may be at greater risk of brain shrinkage that occurs with aging and diseases such as dementia, according to new research published in the September 4, 2012, print issue of Neurology-, the medical journal of the American Academy of Neurology.

4 Sep 2012

Exercise paves way to healthy old age

Middle-aged people who have a high level of physical fitness have a significantly lower and later incidence of chronic conditions in old age than those who are less fit, report researchers.

3 Sep 2012

MDA7 compound shows promise against Alzheimer's disease

A compound developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer's disease, according to a study by researchers at Cleveland Clinic's Lerner Research Institute and Anesthesiology Institute.

3 Sep 2012

Study may spur research into multi-model imaging based biomarker development for AD

Alzheimer's disease (AD) is one of the most common brain disorders, with an estimated 35 million people affected worldwide. In the last decade, research has advanced our understanding of how AD affects the brain. However, diagnosis continues to rely primarily on neuropsychological tests which can only detect the disease after clinical symptoms begin. In a supplement to the Journal of Alzheimer's Disease, investigators report on the development of imaging-based biomarkers that will have an impact on diagnosis before the disease process is set in motion.

31 Aug 2012

Research roundup: Readmission risks after surgery; Assessing Medicaid applicants' eligibility; Satisfaction among health plan types

General Surgeons Identify Postoperative Complications Posing Strongest Readmission Risks -- Researchers found that about 11 percent of patients in a study of 1,442 individuals who underwent general surgery were readmitted to the hospital within 30 days.

31 Aug 2012

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Transition Therapeutics Inc. today announced that its licensing partner, Elan Corporation, plc has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes.

31 Aug 2012

New research about brain and related disorders to be unveiled at Neuroscience 2012

New research about the brain and related disorders will be unveiled at Neuroscience 2012 in New Orleans, Oct. 13-17. Findings will include how the brain weighs complex decisions; progress being made in treating Alzheimer's disease, spinal cord injury, and traumatic brain injury; and novel understanding of how life experiences, diet, and sleep influence brain health and wellness.

31 Aug 2012

Alzheimer's Disease News and Research

Further Reading

Experts develop recommendations to determine why nearly two-thirds of Americans with AD are women

Hopes dashed for ginkgo biloba in Alzheimer’s disease

Alzheimer’s disease is not prevented by ginkgo biloba

Eliminating jnk3 enzyme leads to 90% reduction in Alzheimer's plaque-forming compounds

Sleep disruptions may be among the first signs of Alzheimer's

Out-of-pocket spending on health care in old age puts significant strain on finances

Newly discovered neuronal pathway plays key role in controlling bone density during adolescence

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

People with normal blood sugar range may be at increased risk of brain shrinkage

Exercise paves way to healthy old age

MDA7 compound shows promise against Alzheimer's disease

Study may spur research into multi-model imaging based biomarker development for AD

Research roundup: Readmission risks after surgery; Assessing Medicaid applicants' eligibility; Satisfaction among health plan types

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

New research about brain and related disorders to be unveiled at Neuroscience 2012

S107 drug can prevent learning and memory deficits associated with stress-related disorders

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Closing in on neurologic biomarker diagnosis

PrecisionMed announces enrollment of first donor into Amyotrophic Lateral Sclerosis Registry

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News